🧬Chris Moxham - Transcripta Bio - Part 3 | Embracing the Startup Challenge | Mastering Science-to-Business Communication | Building a Scalable Discovery Engine | Leveraging AI & Genetics in Drug Development
Part 3 of 4: Jon Chee hosts Chris Moxham, Co-Founder, CEO, and CSO of Transcripta Bio—a pioneering biotech company accelerating drug discovery to improve lives worldwide.
With a PhD in Molecular and Cellular Pharmacology from Stony Brook University and over 25 years in drug discovery, Chris brings a wealth of experience. During his two-decade tenure at Eli Lilly, he advanced over 10 molecules into clinical trials across multiple therapeutic areas, spanning both small and large molecule modalities.
Chris’s deep expertise and dedication to scientific innovation and team development offer invaluable insights for aspiring biotech leaders.
The Biotech Startups Podcast, brought to you by Excedr—empowering life science startups with founder-friendly equipment leasing to fast-track R&D and drive commercialization success.
Know someone in need of lab equipment? Join Excedr’s referral program: Give your friends $1,000 and earn $1,000 for every qualified referral! 💸
Get your unique referral link here:
refer.excedr.com/ZTHETY.
Part 3 of 4: Jon Chee hosts Chris Moxham, Co-Founder, CEO, and CSO of Transcripta Bio—a pioneering biotech company accelerating drug discovery to improve lives worldwide.
With a PhD in Molecular and Cellular Pharmacology from Stony Brook University and over 25 years in drug discovery, Chris brings a wealth of experience. During his two-decade tenure at Eli Lilly, he advanced over 10 molecules into clinical trials across multiple therapeutic areas, spanning both small and large molecule modalities.
Chris’s deep expertise and dedication to scientific innovation and team development offer invaluable insights for aspiring biotech leaders.
Join us this week to hear about:
- Chris’ transition from Eli Lilly to the startup world, embracing the excitement and uncertainty of a smaller company.
- Navigating investor relations and honing the skill of translating science into business language.
- Developing Transcripta Bio’s discovery engine, a scalable approach to drug discovery.
- Leveraging AI, genetics, and high-throughput data to reduce failure points in drug development.
Please enjoy Jon’s conversation with Chris Moxham.
Find Our Guest, Chris Moxham, at these links:
Find Our Host, Jon Chee, at these links:
Excedr Socials & Website
Enriched Notes:
Topics Mentioned:
People Mentioned:
Timestamps:
00:00 Intro
02:12 Chris's Transition to Fulcrum: moving from Big Pharma to a smaller Biotech
03:42 Mastering investor relations and learning to translate science into business language
06:07 Lessons from an IPO and building rapport with investors
08:00 Life as CSO of a Public Company and the importance of media training
14:57 Building Transcripta Bio’s Discovery Engine and repurposing to accelerate value creation
20:08 Leveraging AI in drug discovery and creating new opportunities in CNS and oncology
23:52 Scaling drug discovery innovation and building the Drug-Gene Atlas
25:09 Outro